- Home
- WWW vs RAPT Comparison
WWW vs RAPT Comparison
Compare WWW & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WWW | RAPT |
|---|---|---|
| Founded | 1883 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2001 | 2019 |
Fundamental Metrics
Financial Performance| Metric | WWW | RAPT |
|---|---|---|
| Price | $20.06 | $57.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 10 |
| Target Price | $23.25 | ★ $56.22 |
| AVG Volume (30 Days) | 1.1M | ★ 4.2M |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $1,755,000,000.00 | N/A |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $4.83 | N/A |
| P/E Ratio | $26.47 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.58 | $0.71 |
| 52 Week High | $32.80 | $57.98 |
Technical Indicators
Market Signals| Indicator | WWW | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 64.47 | 78.40 |
| Support Level | $16.82 | $32.00 |
| Resistance Level | $20.26 | N/A |
| Average True Range (ATR) | 0.78 | 0.10 |
| MACD | 0.14 | -0.84 |
| Stochastic Oscillator | 70.90 | 92.65 |
Price Performance
Historical ComparisonAbout WWW Wolverine World Wide Inc.
Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.